CHATS: Central Hypothyroidism And Adjusted Thyroxine Dose Study (Chats): Impact Of Increasing Free Thyroxine Levels In Patients With Hypopituitarism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN69841377

Enrollment

Registered

2006-09-29

Start date

2005-09-23

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine: Hypopituitarism Nutritional, Metabolic, Endocrine Hypopituitarism

Interventions

Arm A: Thryoxine Arm B: Placebo

Eligibility

Inclusion criteria

Inclusion criteria: Patients (aged 20-70) with hypopituitarism and low-normal free thyroxine levels.

Exclusion criteria

Exclusion criteria: 1. Age 70 years 2. Inability to give informed consent 3. Obvious or suspected poor compliance 4. Thyrotoxicosis 5. Severe concomitant illness with significant impact on life expectancy 6. Active acromegaly or Cushing's disease 7. Uncontrolled cardiac arrhythmias or unstable ischaemic heart disease 8. Treatment with Amiodarone or Lithium within the last 6 months 9. Current treatment with: L-Tri-iodothyronine, Carbimazole, Propylthiouracil

Design outcomes

Primary

Measure	Time frame
QoL assessment with: 1. PGWB (Psychological General Well-Being Schedule) 2. SF-36 (Medical Outcomes Study Short Form?36) 3. EQ-5D (EuroQol EQ-5D) and questionnaires	—

Secondary

Measure	Time frame
1.Thyroid-specific symptom questionnaire 2. QoL assessment with QoL-AGHDA 3. BP, HR 4. fT4, fT3, TSH 5. CK, SHBG 6. Fasting TC, LDL-C, HDL-C, Lp(a) 7. Body composition, BMI 8. ECG and 24 hour Holter ECG 9. Carotid intima-media thickness measurement	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026